Record grant for ANZCA CTN trial

31 May 2022

The CALIPSO trial has been awarded $A8 million by Australia's Medical Research Future Fund.

A heart surgery infection trial endorsed by the Australian and New Zealand College of Anaesthetists (ANZCA) Clinical trials Network (CTN) has been awarded a record $A8 million by the Medical Research Future Fund.

The trial’s principal investigator, Associate Professor Trisha Peel, and Professor Paul Myles, founding chair of the ANZCA CTN, secured the funding to perform a clinical trial in 9000 patients undergoing heart surgery. 

The trial will be co-ordinated at Monash University. It has also been endorsed by the Australasian Society of Infectious Diseases (ASID) Network and is supported by the Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS). 

The trial funding is the highest awarded in the history of the ANZCA CTN and the highest awarded trial in the Rare Cancers, Rare Diseases and Unmet Need grant initiative.

Infections following heart surgery lead to significant patient suffering and healthcare costs. The Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (CALIPSO) is an innovative, adaptive trial that will examine the optimal duration of antibiotic therapy to prevent these infections.

Read the media release.

 

Last updated 11:36 31.05.2022